The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease
- PMID: 32056720
- DOI: 10.1016/j.rmed.2019.105857
The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease
Abstract
Inhalation therapy is the mainstay of chronic obstructive pulmonary disease management, and inhaler selection can have a profound impact on drug delivery and medication adherence, as well as on treatment outcomes. Although multiple delivery systems, such as pressurized metered-dose inhalers, dry powder inhalers, slow-mist inhalers, and nebulizers, are available, clinical benefits achieved by patients rely on effective delivery of the inhaled medication to the airways. Among several factors influencing drug deposition, inspiratory flow is one of the most important. Inspiratory flow impacts drug delivery and subsequent clinical efficacy, making it necessary to adequately train patients to ensure correct inhaler use. Peak inspiratory flow is the maximal airflow generated during a forced inspiratory maneuver. Health care professionals need to select the appropriate delivery system after carefully considering patient characteristics, including lung function, optimal inspiratory flow, manual dexterity, and cognitive function. Herein, the role of inspiratory flow in the selection and use of inhaled therapy in patients with COPD is reviewed.
Keywords: Chronic obstructive pulmonary disease; Hand-held inhalers; Inhalation technique; Inspiratory flow; Peak inspiratory flow.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest Donald A. Mahler has participated in advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sunovion, and Theravance. He is on the speakers’ bureau for AstraZeneca, Boehringer Ingelheim, and Sunovion. He has received royalties from Hillcrest Media for COPD: Answers to Your Question, 2015; CRC Press for Dyspnea: Mechanisms, Measurement, and Management, 3rd edition, 2014; and pharmaceutical companies for use of the baseline and transition dyspnea indexes.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
